Literature DB >> 20381828

Prognostic value of the X-linked inhibitor of apoptosis protein for invasive ductal breast cancer with triple-negative phenotype.

Jinjing Wang1, Yixin Liu, Ru Ji, Qiang Gu, Xiulan Zhao, Yanrong Liu, Baocun Sun.   

Abstract

Molecular classification has raised new hopes of improving our understanding of breast cancer. Discovery of novel tumor markers that allow the identification of patients at higher risk for invasive ductal breast cancer with triple-negative phenotype remains a research and clinical priority. To evaluate the prognostic value of the X-linked inhibitor of apoptosis protein for invasive ductal breast cancer with triple-negative phenotype by correlating the expression of X-linked inhibitor of apoptosis protein with clinicopathologic parameters, thus determining its role in predicting tumor outcomes, 200 cases of patients with invasive ductal breast cancer, including their complete information, were obtained. Tissue microarrays were constructed; and immunohistochemical staining was performed to detect the expression of the estrogen receptor, progesterone receptor, HER2/neu, Ki-67, and X-linked inhibitor of apoptosis protein. We identified 42 cases of invasive ductal breast cancer with triple-negative phenotype. Of these, X-linked inhibitor of apoptosis protein expression was detected in 32 patients (80%). Significant correlations were found between X-linked inhibitor of apoptosis protein expression and primary tumor size (P = .027), and between X-linked inhibitor of apoptosis protein expression and Ki-67 index (P = .038). Kaplan-Meier survival analysis revealed a pattern of X-linked inhibitor of apoptosis protein expression with impaired overall and disease-free survival in patients with the disease. Most importantly, multivariate analysis also showed statistically significant worse outcomes for patients with tumors exhibiting X-linked inhibitor of apoptosis protein expression of at least 50% compared with those with X-linked inhibitor of apoptosis protein expression less than 50%. In conclusion, our results suggest that X-linked inhibitor of apoptosis protein is a novel biomarker and viable prognostic factor for invasive ductal breast cancer with triple-negative phenotype. Furthermore, the expression of X-linked inhibitor of apoptosis protein is significantly correlated with a more aggressive tumor phenotype and decreased overall and disease-free survival. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20381828     DOI: 10.1016/j.humpath.2010.01.013

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  10 in total

Review 1.  Targeting inhibitors of apoptosis proteins (IAPs) for new breast cancer therapeutics.

Authors:  Shaomeng Wang; Longchuan Bai; Jianfeng Lu; Liu Liu; Chao-Yie Yang; Haiying Sun
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-09-29       Impact factor: 2.673

2.  Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.

Authors:  Nobumichi Ohoka; Yoko Morita; Katsunori Nagai; Kenichiro Shimokawa; Osamu Ujikawa; Ikuo Fujimori; Masahiro Ito; Youji Hayase; Keiichiro Okuhira; Norihito Shibata; Takayuki Hattori; Tomoya Sameshima; Osamu Sano; Ryokichi Koyama; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  J Biol Chem       Date:  2018-03-15       Impact factor: 5.157

3.  Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.

Authors:  Sabine M Brouxhon; Stephanos Kyrkanides; Xiaofei Teng; M Kerry O'Banion; Robert Clarke; Stephen Byers; Li Ma
Journal:  Mol Carcinog       Date:  2013-06-18       Impact factor: 4.784

4.  Concomitance of downregulated active caspase-3 and upregulated X-chromosome linked inhibitor of apoptosis protein as a sensitive diagnostic approach for breast cancer.

Authors:  Samir F Zohny; Mazin A Zamzami; Mohamed El-Shinawi
Journal:  Mol Cell Biochem       Date:  2018-11-16       Impact factor: 3.396

5.  XIAP expression is associated with pancreatic carcinoma outcome.

Authors:  Shengmian Li; Jianjian Sun; Jian Yang; Lan Zhang; LE Wang; Xiaoling Wang; Zhanjun Guo
Journal:  Mol Clin Oncol       Date:  2013-01-02

6.  Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez).

Authors:  Yousra Akasbi; Sanae Bennis; Fouad Abbass; Kawtar Znati; Khalid Amrani Joutei; Afaf Amarti; Omar El Mesbahi
Journal:  BMC Res Notes       Date:  2011-11-16

7.  Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model.

Authors:  Pierre-Simon Bellaye; Alexandra Oudot; Jean-Marc Vrigneaud; Olivier Raguin; Francis Bichat; Anne Vaslin; Hélène Maby-El Hajjami; Claudio Zanna; Grégoire Vuagniaux; Pierre Fumoleau; Franck Denat; François Brunotte; Bertrand Collin
Journal:  Contrast Media Mol Imaging       Date:  2018-12-02       Impact factor: 3.161

8.  Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis.

Authors:  Qiang Wu; Guangzhi Ma; Yunfu Deng; Wuxia Luo; Yaqin Zhao; Wen Li; Qinghua Zhou
Journal:  Front Oncol       Date:  2019-10-17       Impact factor: 6.244

Review 9.  XIAP's Profile in Human Cancer.

Authors:  Huailu Tu; Max Costa
Journal:  Biomolecules       Date:  2020-10-29

Review 10.  TRIM32: A Multifunctional Protein Involved in Muscle Homeostasis, Glucose Metabolism, and Tumorigenesis.

Authors:  Simranjot Bawa; Rosanna Piccirillo; Erika R Geisbrecht
Journal:  Biomolecules       Date:  2021-03-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.